CLIA Waiver for Digital Result Group A Strep Test
BD Diagnostics has received 510(k) clearance and CLIA Waiver from the FDA for the BD Veritor™ System for Rapid Detection of Group A Strep. This is the first commercially available rapid Group A Strep test system that incorporates a digital result to receive CLIA Waiver. The new assay is cleared for use in hospitals, outpatient clinics and other patient-care settings.
When used in conjunction with the BD Veritor System Reader, the Group A Strep test utilizes Advanced Nano-particle and Adaptive Read technologies to obtain an accurate result while providing objective results on a hand held reader with an easy-to-read digital display. This digital immunoassay (DIA) for Rapid Detection of Group A Strep offers healthcare professionals a new option for Group A Strep testing versus current visual read CLIA-waived assays.
The BD Veritor System for Rapid Detection of Group A Strep joins the previously FDA-cleared and CLIA-waived BD Veritor™ System for Rapid Detection of Flu A+B and FDA-cleared BD Veritor™ System for Rapid Detection of Respiratory Syncytial Virus. These assays work in conjunction with the BD Veritor System Reader. BD plans to continue to launch additional assays on this new platform.
Tags: Influenza, Respiratory Syncytial Virus, Group A Streptococcus
Date Published: March 10, 2014
Source article link: BD diagnostics » company contact details
Are You Prepared for the Flu Season Ahead?
Arup Offers Explify™ Respiratory a NGS Test for Respiratory Infections
New Primer Pairs for LDTs for P. jirovecii, Group C and G Strep
Discover VirClia®, Chemiluminescence in Monotest That Adapts to Your Lab